Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin

Hepato-Gastroenterology

Volumn 54, Issue 73, 2007, Pages 218-223

  Li, Sheng ^a   Niu, Zuoxing ^a   Tian, He ^a   Zhang, Bo ^a   Wang, Fangxin ^a   Yi, Long Hai ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Gemcitabine; Hepatocellular carcinoma; Multidrug resistance; Oxaliplatin; Systemic chemotherapy

Indexed keywords

ALCOHOL; ANTIEMETIC AGENT; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 34047154392     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bosch FX, Munoz N: Prospects for epidemiological studies on hepatocellular cancer as a model for assessing viral and chemical interactions. IARC Sci Publ 1988; 89:427-438.
2. Hiraoka T, Katayama K, Tanaka J, Ohno N, Joko K, Komiya Y, et al: Lack of epidemiological evidence for a role of resolved hepatitis B virus infection in hepatocarcinogenesis in patients infected with hepatitis C virus in Japan. Intervirology 2003; 46(3):171-176.
3. Wildi S, Pestalozzi BC, McCormack L, Clavien PA: Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004; 91(4):400-408.
4. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27(6):1578-1583.
5. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, et al: Overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12(2):111-126.
6. Huang MS, Lin Q, Jiang ZB, Zhu KS, Guan SH, Li ZR, Shan H: Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10(6):825-829.
7. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK: Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10(5):649-653.
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734-1739.
9. Ng IO, Liu CL, Fan ST, Ng M: Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113:355-363.
10. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 1990; 50(14):4417-4422.
11. Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, et al: Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J Gastroenterol 2003; 9(11):2561-2564.
12. Graziadei I, Kelly T, Schirmer M, Geisen FH, Vogel W, Konwalinka G: Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells. Hepatol 1998; 28(3):504-509.
13. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89(4):750-756.
14. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, et al: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003; 98(12):2664-2670.
15. Guan Z, Wang Y, Maoleekoonpairoj S, Ducreux M, Boleslawski E, Tigaud JM, et al: Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003; 89(10):1865-1869.
16. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al: Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 2003; 22:252.
17. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44(2):117-123.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47(1):207-214.
19. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403-2413.
20. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82(12):1046-1050.
21. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, et al: Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002; 25(2):198-203.
22. Thomas AL, Cox G, Sharma RA, et al: Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36(18):2329-2334.
23. Lai EC, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J: Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990; 66(8):1685-1687.
24. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62(3):479-483.
25. Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, et al: A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 44(4):307-311.
26. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS: Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997; 15(3):257-260.
27. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, et al: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91(1):101-105.
28. Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Adenis A, et al: A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Ann Oncol 1997; 8(5):500-502.
29. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, et al: Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78(1):34-39.
30. Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, et al: A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001; 37(11):1352-1358.
31. Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A: A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 1999; 86(3):410-414.
32. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21(18):3402-3408.
33. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M: II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48(39):783-789.
34. Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B, Raderer M, Scheithauer W: Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001; 60(4):313-315.
35. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, et al: A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94(12):3186-3191.
36. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC: Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 2002; 13(11):1771-178.
37. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, et al: Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carbo-platinum. Biomed Pharmacother 1989; 43(4):237-250.
38. Jennerwein MM, Eastman A, Khokhar A: Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem Biol Interact 1989; 70(1-2):39-49.
39. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003; 66(2):225-237.
40. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54(13):3500-3505.
41. Scheeff ED, Howell SB: Computer modeling of the primary cisplatin and oxalipatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition. Proc Am Assoc Cancer Res 1998; 39:158.
42. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9(10):1053-1071.
43. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: nal results of a GERCOR multicenter Phase II study. J Clin Oncol 2002; 20:1512-1518.
44. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, et al: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13:1479-1489.
45. Becouarn Y, Agostini C, Trufflandier N, Boulanger V: Oxaliplatin: avalable data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 2001; 40(3):265-272.
46. Ulrich-Pur H, Kornek GV, Raderer M, Haider K, Kwasny W, Depisch D, et al: A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 2000; 88(11):2505-2511.
47. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, et al: Two consecutive phase II studies of 5-fluorouracil/leucovorin/ mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56(3):177-180.
48. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12(6):1323-1334.